Skip To Main Content
C. M. Barysauskas on Muck Rack

C. M. Barysauskas

As seen in: Annals of Oncology, The Journal of Hospital Infection
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with C. M.

Contact C. M., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

The Association of Hospital Contact Precaution Policies with Emergency Department Admission Time

|
By C. M. Barysauskas, K. Kotkowski, R. T. Ellison, B. Barton
| The Journal of Hospital Infection Verified
Publication HistoryPublished online: March 24, 2017Accepted: March 20, 2017; Received: September 30, 2016;
Open in Who Shared Issue with article?

Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy

|
By E. Ben-Ami, C. M. Barysauskas, M. von Mehren, M. C. Heinrich, C. L. Corless
| Annals of Oncology Verified
Background This investigator-initiated trial provided the justification for the phase III GRID study resulting in worldwide regulatory approval of regorafenib as a third-line therapy for patients with metastatic gastrointestinal stromal tumors (GIST). We report the genotype analyses, long-term safety, and activity results from this initial trial of regorafenib in GIST.
Open in Who Shared Issue with article?
See all 2 articles